Analysts expect Scholar Rock Holdings Inc. (NASDAQ:SRRK) to report $1.02 EPS


Wall Street brokers expect Scholar Rock Holding Co (NASDAQ: SRRK – Get Rating) to earn $1.02 per share for the current fiscal quarter, Zacks Investment Research reports. Zero Analysts have released ScholarRock’s earnings estimates. The lowest estimate for EPS is ($1.17) and the highest estimate is ($0.86). Scholar Rock reported earnings of $0.84 per share in the same quarter last year, indicating a negative annual growth rate of 21.4%. The company is expected to announce its next quarterly earnings results on Monday, January 1st.

On average, analysts expect ScholarRock to report full-year earnings ($3.16) per share for the current fiscal year, with EPS estimates ranging from ($3.96) to ($2.71). For the next year, analysts expect the company to report earnings of $3.36 per share, with EPS estimates ranging from $3.99 to $2.42. Average earnings per share from Zacks Investment Research is an average based on a survey of sell-side analysts covering Scholar Rock.

Scholar Rock (NASDAQ: SRRK – Get Rating) released its latest quarterly earnings data on Monday, March 7. The company reported ($0.97) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.05) by $0.08. ScholarRock has a net negative margin of 236.95% and a negative return on equity of 59.99%. The company generated $4.05 million in revenue for the quarter, compared to the consensus estimate of $4.33 million. During the same period in the previous year, the company ($2.81) earned earnings per share.

A number of research analysts recently commented on SRRK’s stock. Wedbush lowered its price target for Scholar Rock shares from $50.00 to $33.00 and assigned a “na” rating to the stock in a research report on Tuesday, May 17th. Zacks Investment Research upgraded shares of ScholarRock from a “hold” rating to a “buy” rating and set a $6.50 target price per share in a research report on Wednesday, May 11th. HC Wainwright began covering shares of Scholar Rock in a research report on Wednesday, March 23rd. They have assigned a “buy” rating and a $24.00 target price per share. BMO Capital Markets lowered its price target for ScholarRock shares from $74.00 to $55.00 in a research report on Tuesday, May 17. Finally, Piper Sandler lowered its target price for Scholar Rock shares from $56.00 to $28.00 and assigned an “overweight” rating to the stock in a report released on Monday, May 16. One analyst has rated the stock with a hold rating and three analysts have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, ScholarRock currently has an average rating of “Buy” and an average price target of $29.08.

Institutional investors and hedge funds have recently bought and sold shares of stock. TD Asset Management Inc. Its stake in ScholarRock increased 28.9% in the fourth quarter. TD Asset Management Inc. Now 148,964 shares of the company’s stock are valued at $3,700,000 after acquiring an additional 33,393 shares last quarter. BlackRock Inc. increased its stake in ScholarRock by 0.9% during the third quarter. BlackRock now owns 2,198,105 shares of the company’s stock valued at $72,582,000 after purchasing an additional 19,049 shares during the last quarter. IndexIQ Advisors LLC increased its stake in Scholar Rock by 11.1% during the third quarter. IndexIQ Advisors LLC now owns 8,875 shares of the company’s stock, valued at $293,000 after purchasing an additional 889 shares during the last quarter. Wellington Management Group LLP increased its stake in Scholar Rock by 124.9% during the third quarter. Wellington Management Group LLP now owns 1,276,488 shares of the company’s stock valued at $42,150,000 after purchasing an additional 708,831 shares during the last quarter. Finally, Geode Capital Management LLC increased its stake in Scholar Rock by 3.7% during the third quarter. Geode Capital Management LLC now owns 429,137 shares of the company’s stock valued at $14,170,000 after purchasing an additional 15,207 shares during the last quarter. 84.22% of the stock is currently owned by hedge funds and other institutional investors.

Shares of NASDAQ SRRK traded down $0.06 during Monday’s trading, to $5.23. 2,416 shares were traded from the exchange, compared to an average volume of 380,863 shares. The 50-day moving average is $9.88 and the 200-day moving average is $17.93. ScholarRock recorded a twelve-month low at $4.84 and a 12-month high at $44.95. The company’s quick ratio is 4.13, the trading ratio is 6.85, and the debt-to-equity ratio is 0.25. The company has a market capitalization of $184.63 million, a price-earnings ratio of -1.73 and a beta of 0.60.

About Scholar Rock (Get Rating)

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of drugs to treat critical diseases in which signaling by protein growth factors plays an essential role. The company has developed Apitegromab, a latent myostatin activation inhibitor that has completed a Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which is in phase I clinical trials to treat cancers resistant to checkpoint inhibitory therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.

Recommended stories

Get a FREE copy of Zacks’ Scholar Rock (SRRK) Research Report

For more information on Zacks Investment Research’s research offerings, visit Zacks.com

Earnings history and estimates for Scholar Rock Corporation (NASDAQ: SRRK)



Receive Scholar Rock Daily news and reviews Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Scholar Rock and related companies with MarketBeat.com’s free daily email newsletter.

Leave a Comment